Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020

Nabriva Therapeutics

06/02/2023 11:14

Feb 6 (Reuters) - Merck & Co Inc  MRK.N :
    * NABRIVA THERAPEUTICS - ON JAN 31, CO'S UNIT ENTERED INTO
LETTER
AGREEMENT WITH 2 UNITS OF MERCK & CO, ABOUT DISTRIBUTION
AGREEMENT, DATED JULY 15, 2020
    * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S
EXCLUSIVE LICENSE TO DISTRIBUTE, COMMERCIALIZE SIVEXTRO WAS
CONVERTED TO NON-EXCLUSIVE LICENSE
    * NABRIVA THERAPEUTICS - PURSUANT TO LETTER AGREEMENT, CO'S
UNIT
AND MERCK'S 2 UNITS AGREED TO TERMINATE DISTRIBUTION AGREEMENT,
EFFECTIVE JUNE 30
    * NABRIVA THERAPEUTICS - COMPANY NO LONGER INTENDS TO
ACTIVELY
PROMOTE SIVEXTRO
    * NABRIVA THERAPEUTICS - EXPECTS TO CONTINUE TO MAKE
SIVEXTRO
AVAILABLE TO WHOLESALE CUSTOMERS & RECORD REVENUE ON ACCOUNT OF
ANY SALES UNTIL JUNE 30

Further company coverage:  MRK.N 
 ((Reuters.Briefs@thomsonreuters.com;))